VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

ALVAC- CDV-H/F NYVAC- CDV-H/F
Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0004773
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • CDVgp6 haemagglutinin protein H gene engineering:
    • Type: Recombinant vector construction
    • Description: Attenuated vaccinia virus (NYVAC) or canarypox virus (ALVAC) vaccine strains expressing the CDV hemagglutinin (H) and fusion (F) protein genes (NYVAC-HF and ALVAC-HF) (Welter et al., 2000).
    • Detailed Gene Information: Click Here.
  • CDVgp5 gene engineering:
    • Type: Recombinant protein preparation
    • Description: Attenuated vaccinia virus (NYVAC) or canarypox virus (ALVAC) vaccine strains expressing the CDV hemagglutinin (H) and fusion (F) protein genes (NYVAC-HF and ALVAC-HF) (Welter et al., 2000).
    • Detailed Gene Information: Click Here.
  • Preparation: An attenuated canarypox virus (ALVAC) vaccine strain expressing the CDV hemagglutinin (H) and fusion (F) protein genes (ALVAC-HF) (Welter et al., 2000).
  • Immunization Route: intranasal immunization
  • Vaccine Ontology ID: VO_0004772
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • CDVgp6 haemagglutinin protein H gene engineering:
    • Type: Recombinant vector construction
    • Description: Attenuated vaccinia virus (NYVAC) or canarypox virus (ALVAC) vaccine strains expressing the CDV hemagglutinin (H) and fusion (F) protein genes (NYVAC-HF and ALVAC-HF) (Welter et al., 2000).
    • Detailed Gene Information: Click Here.
  • CDVgp5 gene engineering:
    • Type: Recombinant vector construction
    • Description: Attenuated vaccinia virus (NYVAC) or canarypox virus (ALVAC) vaccine strains expressing the CDV hemagglutinin (H) and fusion (F) protein genes (NYVAC-HF and ALVAC-HF) (Welter et al., 2000).
    • Detailed Gene Information: Click Here.
  • Preparation: An attenuated vaccinia virus (NYVAC) vaccine strain expressing the CDV hemagglutinin (H) and fusion (F) protein genes (NYVAC-HF) (Welter et al., 2000).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response Host Response

Ferret Response

  • Vaccination Protocol: Ferrets without maternal antibody were vaccinated intranasally with NYVAC-HF and ALVAC-HF. While ferrets with maternal antibody were vaccinated parenterally with NYVAC-HF and ALVAC-HF (Welter et al., 2000).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: At 12 weeks of age, the ferrets were challenged with CDV (Welter et al., 2000).
  • Efficacy: Combined i.n.-parenteral immunization of ferrets with maternal antibody using NYVAC-HF produced higher titers than did i.n. immunization with NYVAC-HF and ALVAC-HF, and survival was also significantly better in the i.n.-parenteral group than in the other HF-vaccinated animals (none of 18) or in controls immunized with RG. Multiple routes were not tested with the ALVAC vaccine (Welter et al., 2000).

Ferret Response

  • Vaccination Protocol: Ferrets without maternal antibody were vaccinated intranasally with NYVAC-HF and ALVAC-HF. While ferrets with maternal antibody were vaccinated parenterally with NYVAC-HF and ALVAC-HF (Welter et al., 2000).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: At 12 weeks of age, the ferrets were challenged with CDV (Welter et al., 2000).
  • Efficacy: Both the NYVAC and attenuated CDV vaccines protected against the development of some clinical signs of infection. The results suggest that infant ferrets are less responsive to i.n. vaccination (Welter et al., 2000).
References References
Welter et al., 2000: Welter J, Taylor J, Tartaglia J, Paoletti E, Stephensen CB. Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection, using recombinant attenuated poxvirus vaccines. Journal of virology. 2000; 74(14); 6358-6367. [PubMed: 10864646].
Welter et al., 2000: Welter J, Taylor J, Tartaglia J, Paoletti E, Stephensen CB. Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection, using recombinant attenuated poxvirus vaccines. Journal of virology. 2000; 74(14); 6358-6367. [PubMed: 10864646].